Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability
Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability
复制标题
格拉司琼控制骨髓移植相关恶心和呕吐：疗效和耐受性综述
DOI：
10.1007/s00520-003-0480-6
复制
发表时间：
2003
影响因子：
3.1
通讯作者：
H. Prentice
中科院分区：
文献类型：
--
作者：
H. Prentice
接受骨髓移植（BMT）的癌症患者会出现与高剂量化疗药物相关的严重恶心和呕吐;这些呕吐症状与许多预处理方案中使用的全身照射有关。本文综述了5-HT 3受体拮抗剂格拉司琼单药或与其他止吐药联合应用于骨髓移植和外周血干细胞移植（PBSCT）患者的临床经验。临床研究证明了格拉司琼的疗效（47-61%，无呕吐，不超过轻度恶心）和耐受性。其较长的半衰期和作用持续时间可能是其有效控制BMT患者恶心和呕吐的24小时原因。
Cancer patients undergoing bone marrow transplantation (BMT) experience severe nausea and vomiting associated with high-dose chemotherapy agents; these emetic symptoms are compounded by total body irradiation used in many conditioning regimens. This paper reviews clinical experience with the 5-HT3 receptor antagonist granisetron, both as a single agent and in combination with other anti-emetics, in patients undergoing BMT and peripheral blood stem cell transplantation (PBSCT). Clinical studies demonstrate the efficacy (47–61% with no vomiting and no worse than mild nausea) and tolerability of granisetron. Its long half-life and duration of action may be responsible for its effective 24 h control of nausea and vomiting in BMT patients.
影响因子：
2.6
作者：
V. Roy;Lorre Ochs;D. Weisdorf
通讯作者：
V. Roy;Lorre Ochs;D. Weisdorf